Molecular T argeting o f P latelet-Derived G rowth F actor B by I matinib M esylate i n a P atient W ith M etastatic Dermatofibrosarc oma P rotuberans
暂无分享,去创建一个
J. Eary | S. Mirza | E. Conrad | S. Schuetze | B. Rubin | T. Norwood | J. Bruckner
[1] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[2] P. D. Dal Cin,et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. , 2001, Cancer research.
[3] B. Druker,et al. STI571: targeting BCR-ABL as therapy for CML. , 2001, The oncologist.
[4] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[5] M. Emond,et al. Chromosomal changes in a dedifferentiated chondrosarcoma: a case report and review of the literature. , 2001, Cancer genetics and cytogenetics.
[6] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[7] T. Sjöblom,et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. , 1999, Cancer research.
[8] J. Fletcher,et al. Various regions within the alpha‐helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant‐cell fibroblastomas , 1998, Genes, chromosomes & cancer.
[9] G. Sozzi,et al. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans , 1998, Oncogene.
[10] A. D. Dei Tos,et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. , 1998, The American journal of surgical pathology.
[11] H. Mankin,et al. Radiation in management of patients with dermatofibrosarcoma protuberans. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Panicek,et al. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma , 1994, Cancer.
[13] H. Tagami,et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34 , 1992, The British journal of dermatology.
[14] E. Rutgers,et al. Dermatofibrosarcoma protuberans: treatment and prognosis. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] A. Nicastri,et al. Dermatofibrosarcoma Protuberans: An Analysis of 86 Cases Five with Metastasis , 1967, Annals of surgery.
[16] J. Dumanski,et al. Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastoma , 1997, Nature Genetics.